Desarius

Quick links to important sections

Desarius

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Desarius

This overview establishes the core identity, composition, and general purpose of the medicine Desarius, using authoritative facts and a patient-friendly structure.

Property Description
Active ingredient Desloratadine (INN)
Form Tablets (film-coated, orally disintegrating) or Oral solution
Pharmacological class Second-generation H1-Antihistamine
Common use Systemic relief from allergic manifestations
Origin Synthetic, Active metabolite of Loratadine

What Type of Medicine is Desarius? (Identity and Classification)

Desarius is a trade name for the active ingredient Desloratadine, which is classified as a second-generation antihistamine. It is a synthetic substance intended for systemic use, typically administered via the oral route. The compound is a tricyclic H1-antihistamine, clinically recognized for providing effective symptomatic relief with a differentiated tolerability profile compared to older agents.

Desloratadine is a single active substance product available in several dosage forms, including film-coated tablets, oral solution, and orally disintegrating tablets. The oral solution form is often marketed toward pediatric patient groups, offering a flexible, non-solid dosage option.


Desloratadine: Composition and General Purpose

The medication is composed of the active ingredient Desloratadine (INN), which is chemically the major active metabolite of Loratadine. This means Desloratadine is the direct therapeutic agent, not requiring conversion in the body to exert its effect. Desloratadine belongs to the class of selective H1-antagonists.

The general purpose of this pharmaceutical is to provide systemic relief by interrupting the body's allergic response. It accomplishes this by acting as a selective H1-receptor antagonist, blocking the effects of histamine released during allergic reactions. As a second-generation compound, Desloratadine is categorized as a long-acting, non-sedating antihistamine in most individuals, designed to provide sustained suppression of allergic symptoms over an extended duration, which is useful in managing recurring seasonal discomforts.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Desarius?

Possible Side Effects and Safety Information

The safety profile of Desarius is based on official data from clinical trials and post-marketing surveillance, classifying possible effects by frequency and the body system affected. These classifications reflect how government regulatory documents organize and communicate the medicine's safety profile.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized into frequency tiers. The most frequent reactions reported in excess of placebo, categorized as Common (affecting 1% to 10% of users), include headache, dry mouth, and fatigue.

Events reported as Very Rare (affecting less than 1 in 10,000 users) or Frequency Not Known are primarily documented through post-marketing reports and affect various organ systems.

System-Organ Classes and Serious Reactions

Official labels group adverse effects by the physiological system impacted. The most significant documented effects involve the following systems:

  • Nervous System Disorders: Documented effects include dizziness, somnolence, insomnia, and, very rarely, seizures.
  • Hepatobiliary Disorders: Very rare reports include elevated liver enzymes, increased bilirubin, hepatitis, and jaundice.
  • Cardiac Disorders: Serious events reported with an unknown frequency include tachycardia, palpitations, QT prolongation, and arrhythmia.
  • Psychiatric Disorders: Includes very rare reports of hallucinations and post-marketing reports of abnormal behaviour and aggression.
  • General Disorders: Very rare serious adverse reactions include severe hypersensitivity reactions such as anaphylaxis and angioedema.

Population-Specific Safety Considerations

The regulatory label includes specific safety notes for certain patient populations. Caution is required in patients with severe renal insufficiency or severe hepatic impairment due to altered drug exposure. For the pediatric population, specific post-marketing reports have indicated an increased incidence of new-onset seizures.

Regulatory documents state that Desarius is contraindicated in individuals with known hypersensitivity to the active ingredient, any of its excipients, or to Loratadine (its parent compound). Caution is also advised when using the medicine alongside alcohol due to post-marketing reports of intolerance.

Overdose and Emergency Response

Overdose and When to Seek Help

The official product labeling for Desloratadine (Desarius) addresses potential overdose scenarios by defining documented clinical manifestations and emergency response requirements.

Documented Overdose Manifestations

Overdose generally presents with an adverse event profile that is similar to effects seen at therapeutic doses, such as drowsiness, headache, and agitation, although the magnitude of these effects can be higher. Of serious concern, post-marketing reports indicate the potential for severe, life-threatening outcomes, including seizures, cardiac arrhythmia, and QT prolongation. The potential for new-onset seizures has been specifically noted in patients 0 to 19 years of age.

Emergency Action and Management

In the event of any suspected overdose, it is mandated to seek immediate medical attention or contact a poison control center. Emergency services must be contacted immediately if the individual is collapsed, having trouble breathing, or cannot be awakened.

Management of Desloratadine overdose is strictly symptomatic and supportive. Regulatory documents recommend considering standard measures to remove unabsorbed substance. Due to the nature of the compound, the official label explicitly states that Desloratadine is not eliminated by haemodialysis, and no specific antidote is available. Hospital monitoring, including cardiac monitoring and ECG assessment, may be necessary due to the risk of serious cardiac effects.

Therapeutic Uses of Desarius

Desarius is relevant across domains where supportive symptomatic support is needed for allergic conditions. The medication is commonly used to help manage the disruptive symptoms associated with two primary conditions: allergic rhinitis and chronic urticaria.


Managing Symptomatic Discomfort

Desarius is applied in clinical settings that involve acute or unstable symptom patterns of hay fever and year-round allergies. The medication is relevant for easing symptom clusters that may become heightened, such as repetitive sneezing, runny nose (rhinorrhea), and inner nasal itching, alongside associated ocular symptoms like tearing and redness.

Brief Indication Listing: The medicine is commonly used to help with conditions presenting with systemic or localized discomfort, including seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria.

The medication also addresses the pronounced manifestations of allergic skin conditions. It assists with the management of discomforting skin itching (pruritus) and supports the management of the visible manifestations of hives. This support helps improve day-to-day comfort during symptomatic periods, especially when symptoms create noticeable physiological strain.


Patient Benefit and Stability

This supportive relief contributes to easing the overall symptom burden and helps maintain a sense of stability when chronic skin symptoms are more noticeable or when rhinitis symptoms create noticeable physiological strain. Desarius is applied in scenarios where additional management of discomfort is required to assist with maintaining functional stability.

Quick Fact: Used for managing Pruritus (Itching)

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Desarius (desloratadine) eligibility is defined by regulatory documents based on age, hypersensitivity, and physiological status.

Contraindications and Restrictions

Desarius is contraindicated in patients with known hypersensitivity to the active substance Desloratadine, its parent compound Loratadine, or any ingredient in the formulation.

Age Group Eligibility Status Regulatory Requirement
Adults & Adolescents Approved for those 12 years and older. Standard eligibility.
Infants (Under 6 months) Not established or Not recommended. Safety and efficacy data are insufficient for this age group.

Conditional Use and Special Populations

Use is not recommended in pregnant women as a precautionary measure, and it is not recommended in breastfeeding women because the drug is excreted into human milk. A decision must be made to discontinue nursing or the therapy.

Use requires caution in patients with a history of seizures and in adults with severe renal (kidney) or hepatic (liver) impairment. For adults with kidney or liver impairment, a reduced starting regimen (e.g., a tablet every other day) is typically recommended by regulators.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Desarius (Desloratadine) has been studied for interactions with certain medications that affect drug metabolism. The primary interactions involve products that may increase the level of Desarius in the body.

Product Category/Name Interaction Mechanism Clinical Relevance
Macrolide Antibiotics (e.g., Erythromycin) Increased plasma concentration (AUC and C max) of Desarius and its active metabolite (3-hydroxydesloratadine). Not associated with clinically relevant changes in the safety profile, including no effect on the corrected QT interval (QTc) in healthy volunteers.
Azole Antifungals (e.g., Ketoconazole) Increased plasma concentration (AUC and C max) of Desarius and its active metabolite. Not associated with clinically relevant changes in the safety profile, including no effect on the QTc interval in healthy volunteers.

Other Relevant Context

Special Population Notes: Exposure to Desarius may be significantly higher in individuals who are considered slow metabolizers of the drug. Similarly, patients with severe hepatic impairment may have a slower clearance of Desarius, resulting in increased systemic levels. No specific dosing adjustments based on drug-drug interactions with Erythromycin or Ketoconazole are specified in the official labeling, as the increases in concentration were not found to be clinically significant regarding safety in studies.

Mechanism of Action

Selective Blockade of the Histamine H1 Receptor

Desloratadine's primary action involves highly specific antagonism of the peripheral histamine H1 receptor ( H1R), stabilizing the receptor in an inactive state to prevent activation by histamine. This molecular blockade immediately interrupts the H1R-mediated signaling cascade, preventing the increase in vascular permeability and the direct excitation of sensory nerves.

Modulation of Downstream Inflammatory Processes

The mechanism extends beyond receptor blockade through H1R-independent activity that modulates the exocytosis of secondary inflammatory mediators from immune cells like mast cells and basophils. By suppressing the release of substances beyond histamine (e.g., certain leukotrienes and chemokines), this action modulates the inflammatory signaling cascade and restricts the migration of inflammatory cells into tissues.

Restricted Peripheral Action

A defining feature of the mechanism is its peripheral selectivity, conferred by the molecule's restricted passage across the blood-brain barrier (BBB) due to its interaction with the P-glycoprotein efflux pump. This physiological constraint ensures the drug's activity is concentrated in peripheral systems, resulting in the attenuation of histamine-driven signaling without affecting central neurotransmitter function.

Dosage and Administration Information

Administration Guidelines for Desarius (5 mg)

The use of Desarius (desloratadine) follows standard guidelines for appropriate administration.

Administration Scope

Desarius is an oral medication, administered as a tablet, with specific rules governing its route, dosage, and timing.

Classification Rule
Route of Administration Oral (tablet)
Dosing Schedule 5 mg
Frequency Once daily
Timing in Relation to Meals May be taken without regard to meals.

Procedural Steps and Age Constraints

The required dosage is 5 mg taken once every 24 hours. The tablet must be swallowed whole. The administration time relative to food is flexible, as its bioavailability is not significantly affected by meals or grapefruit juice. No preparation steps, such as dilution or shaking, are required for the tablet formulation.

The following age constraint for use is specified:

  • Age-Group Administration Rule: Desarius is indicated for use in adults and adolescents 12 years of age and older.

Overall Use Protocol

This medication is structured around a simple, fixed-dose, once-daily oral regimen (5 mg) that is independent of mealtimes. This protocol ensures consistent systemic exposure to the active substance. All usage must comply with the specified age group, and the once-daily administration frequency should be maintained.

Recent Clinical Evidence

Desarius: Recent Clinical Evidence

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Desarius was studied for allergic rhinitis primarily in short-term Randomized Controlled Trials (RCTs) and supporting Meta-analyses. These studies examined patient-reported experiences in seasonal and perennial forms, focusing on episodes where symptoms become more noticeable. Researchers tracked outcomes related to physical discomfort, using Total Symptom Scores (TSS), individual symptoms (like runny nose, sneezing), and functional assessments like quality of life and nasal airflow. While evidence contributes to the broader evidence landscape, long-term outcomes beyond the initial weeks or months are not fully established. Regulatory reviews also note limited trial experience for efficacy in the adolescent age group (12 to 17 years).


Evidence for Use in Chronic Urticaria (Hives)

Desarius was evaluated in clinical settings for Chronic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations. Research examined symptoms like pruritus (itching) and the number of wheals (hives) in short-term RCTs and reviews. Studies explored outcomes reflecting daily functioning, and the evidence contributes to understanding symptom patterns. However, scientific reviews indicate evidence quality varies across studies for specific functional outcomes, and certainty remains low for some duration and dosing patterns. Recurrence was observed in some studies, and research does not determine whether an individual will respond similarly to the group patterns reported.


Studies in Special Populations and Long-Term Findings

The available research includes dedicated studies for Children, with trials starting from six months and older. Research examined age-appropriate assessments and monitored subgroups such as individuals identified as slow metabolizers or patients with kidney or liver conditions. Results apply only to the populations studied, and data for certain groups remain insufficient. The majority of pivotal evidence consists of research exploring short-term symptom changes, as follow-up durations were limited. Long-term effects are not fully established regarding the durability of findings or the impact of continuous use.


What is Still Uncertain About the Research

Scientific reviews indicate several areas where evidence is not complete. Firstly, comparative evidence is lacking against all similar treatments. Secondly, findings were mixed when assessing specific objective measurements in some study cohorts. Finally, the existing body of evidence provides limited insight into how sustained the observed changes are. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Desloratadine Drug Information

Frequently Asked Questions (FAQ)

Common questions about Desarius (FAQ)


Q: Does Desarius interact with alcohol, and if so, how?

Official caution is advised when using the medicine alongside alcohol, due to post-marketing reports of intolerance. This caution is based on the possibility that alcohol may increase the risk of side effects such as drowsiness or dizziness.


Q: Can Desarius be used by older adults (e.g., over 65)?

Official regulatory documents indicate that patients 12 years of age and older are eligible for use. As with many medicines, older patients are sometimes considered to be more sensitive to the drug's effects, and clinical guidance is sometimes needed.


Q: Can children or adolescents use Desarius?

This medicine is indicated for use in adolescents who are 12 years of age and older. For specific conditions and formulations, regulatory documentation states it may be used in children as young as 6 months, following specific guidance.


Q: Does Desarius need to be taken at a specific time of day (morning or evening)?

The recommended dosing schedule is once daily, and the tablet can be taken with or without food. Official regulatory documents do not state a required time of day (morning or evening) for administration.


Q: Is Desarius safe to use during pregnancy or while breastfeeding?

Official documents state that use of this medicine is generally not recommended during pregnancy as a precaution. Use is also not recommended while breastfeeding because the drug is known to pass into human breast milk.


Q: Are there any specific activities, like driving, that should be approached with caution when taking Desarius?

While most people do not experience impairment, official safety information notes that due to the possibility of drowsiness or dizziness, caution is appropriate before engaging in activities like driving or operating machinery.


Q: What makes Desarius different from other similar treatments I've heard of?

Regulatory classification identifies Desarius (desloratadine) as the active metabolite of loratadine (its parent compound). It is classified as a second-generation H1-antihistamine and is generally described as non-sedating because it does not easily cross the blood-brain barrier to affect the central nervous system.


Q: Why do official documents sometimes mention 'hepatic impairment' in relation to Desarius?

Official documents mention hepatic impairment (severe liver conditions) because the body clears the drug more slowly in these patients. This slower clearance can lead to increased systemic drug levels, and altered dosing is often guided by a healthcare provider for this population.


Q: Is it normal to feel a bit dizzy when first starting Desarius?

Dizziness is listed in regulatory documentation as an adverse reaction reported in clinical trials. While it occurred in some patients, official sources do not specifically label the experience as 'normal' when first initiating treatment.


Q: What happens if Desarius is taken with common pain relievers like ibuprofen?

Regulatory studies have focused primarily on interactions with certain strong enzyme inhibitors, such as specific antifungal or antibiotic medicines. Official labeling does not report any clinically relevant interactions when Desarius is taken alongside nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.


Q: Is Desarius known to cause fatigue or sleepiness?

Fatigue and somnolence (drowsiness) are listed as common adverse reactions in regulatory documents, reported at rates slightly greater than in patients taking a placebo. However, the medicine is generally classified as a non-sedating antihistamine because it does not readily enter the central nervous system.


Q: Is Desarius used for acute (short-term) or chronic (long-term) issues?

The drug is officially indicated for symptoms associated with both types of allergic rhinitis—seasonal (which can be intermittent) and perennial (which is persistent). It is also used for chronic idiopathic urticaria, meaning it may be used for both short-term symptom relief or continued management.


Q: Is Desarius used to prevent something or to treat an active condition?

The medicine’s official purpose is defined as providing symptomatic relief for active manifestations of allergic rhinitis and chronic idiopathic urticaria, which describes its use as treatment for active symptoms.


Q: How quickly do people typically start to notice the described effects of Desarius?

Pharmacokinetic data indicates the active substance is rapidly absorbed after being taken by mouth. Regulatory summaries often describe the time to effect as typically occurring within one hour.


Q: What happens if I forget to take my Desarius for one day?

Official regulatory guidance states that if a dose is missed, it should generally be taken as soon as possible once remembered. However, if it is close to the time of the next scheduled dose, the missed dose is typically skipped to avoid taking a double dose.


Q: Does Desarius cause weight changes?

Official documentation reports that weight gain has been recorded as an adverse reaction during post-marketing surveillance. This effect is listed with a 'not known' frequency, meaning the specific rate of occurrence in the general population cannot be reliably determined from the available data.


Q: What is the risk of developing a serious allergic reaction to Desarius?

Serious hypersensitivity reactions, such as anaphylaxis (a severe, life-threatening reaction), have been reported during the post-marketing period. Regulatory documents classify these events as 'very rare' or having a 'not known' frequency.


Q: Is Desarius a controlled substance?

Based on official drug classification records from major government agencies, this medicine is not currently designated as a controlled substance under regulatory scheduling.


Q: Why is a prescription needed for Desarius?

In many regions, this medicine is designated as a prescription-only product. This status ensures that a healthcare professional can assess the patient's individual health history, including their liver and kidney function, before authorizing its use.


Q: How long after stopping Desarius does it stay in the body?

Pharmacokinetic studies indicate the medicine has a long duration of action, with an elimination half-life of approximately 27 hours in most individuals. This half-life refers to the time it takes for the amount of medicine in the body to decrease by half.


Q: Is there a generic version of Desarius available?

Yes, regulatory authorities have confirmed that generic versions of the active ingredient Desloratadine are authorized for use in many major markets. These generics have been verified to demonstrate comparable quality and bioequivalence to the original reference medicine.


Q: What is the most frequently reported side effect of Desarius?

Based on controlled clinical trials in adults and adolescents, the most frequently reported adverse event that occurred at a rate greater than placebo was headache.


Q: Why might a doctor stop a patient from taking Desarius suddenly?

Regulatory documents suggest that discontinuing the medicine may be considered necessary if a patient develops a serious hypersensitivity reaction (like anaphylaxis) or if they experience a new-onset seizure while they are receiving treatment.

How should Desarius be stored and disposed of?

How to Store and Dispose of Desarius (Desloratadine)

Storage of Desarius must adhere to regulatory requirements to ensure product stability and safety. The medicine should be stored at controlled room temperature, typically between 15^circC and 30^circC (59^circF to 86^circF), and must be kept from freezing or exposure to excessive heat or moisture.

Protect the medicine by keeping it in its original container, tightly closed, and away from direct light. Tablets supplied in a bottle are stable for 3 months after first opening. All forms of Desarius must be stored out of the sight and reach of children.

Disposal of unused or expired medicine must follow official guidelines. The product should be disposed of via drug take-back programs or by mixing with an undesirable substance before discarding in household trash, as Desarius is not on the list of medicines approved for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Desarius found in:

A-Z Index: